The Pharma Career Ladder · The medical rep · Step 3: Knowing the science · Lesson 2

Reading a clinical paper

Four steps from the abstract to the limitations

By Ahmed El Menshawy · 20 years in pharma, from medical rep to country manager in the UAE. Founder of RepPharma. LinkedIn
Published

Most reps know the headline result of their key trial. Far fewer can tell a doctor who was actually in it.

That gap shows the moment a specialist asks one question beyond the slide. The rep who read only the abstract has nothing left to say.

The four steps I ask reps to climb with every key paper:

  • 1. Abstract. The main claim in one paragraph. Where you start, never where you stop.
  • 2. Methods. Who was studied, against what, and for how long. Ask yourself: would these patients sit in my doctor's clinic?
  • 3. Numbers. The primary endpoint, the absolute difference and the confidence interval. Primary first. Secondary results with care.
  • 4. Limitations. What the authors themselves admit. Doctors respect a rep who knows these.

Step two is the one that changes your calls. Once you know who was in the trial, you know which of the doctor's patients it speaks to.

“If you only read the abstract, you are selling someone else's summary.”
Reading a clinical paper: Four steps from the abstract to the limitations

Lesson 2 of 11 in Step 3: Knowing the science, with the full guide and a checklist for this week.

More lessons in step 3: Knowing the science

Knowing the science, in RepPharma

Log a visit in seconds

The doctor, products detailed, samples and outcome, on an offline-first Android app. Visits save without signal and send when it returns.

A month of visits in seconds

Smart monthly plans are drafted from each doctor’s priority, required visit frequency and best time to visit. The manager approves in one click.

Your KPIs in your pocket

The KPIs agreed with your manager appear in your own app, so you always know where you stand.

A new step every week in the Pharma Career Ladder newsletter on LinkedIn.